Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

Participated · Series A · May 2026

cAMPfield Therapeutics is a newly formed biotechnology company backed by Mountainfield Venture Partners and other life-science investors to advance licensed development-stage therapeutic candidates. Its CEO, Bill Gerhart, has more than two decades of experience in pulmonary, fibrosis, and inflammatory diseases and a track record of leading biotech exits. Other senior leaders include CTO Patricia Turney and global head of regulatory affairs Rita Shah. Public filings and reporting link cAMPfield to vTv Therapeutics' HPP737, a PDE4 inhibitor that has been studied in China for psoriasis, COPD, atopic dermatitis, and idiopathic pulmonary fibrosis, including an ongoing Phase 3 psoriasis trial there. The company's explicit pipeline needs are not detailed in the coverage, nor are financial metrics beyond the $180 million Series A. cAMPfield appears positioned to progress licensed candidates through clinical development with capital from its recent financing.

Participated · Series A · May 2026

Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Led · Series A · Mar 2026

R1 Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis and is described as a pan phosphate active transport inhibitor that blocks three key phosphate transporters in the gut. R1 positions AP306 as designed to deliver rapid and effective phosphate lowering with a reduced treatment burden. The company is partnering with Alebund on AP306 and plans to start a Phase 2b study later this year. R1 is led by Co-Founder, President and CEO Krishna Polu and is based in Redwood City, CA. The company strengthened its balance sheet with a $77.5M Series A to support its global development program.

Participated · Equity · Dec 2025

Addition Therapeutics is a spin-out from Professor Kathleen Collins’ laboratory at the University of California that focuses on an all-RNA, non-viral lipid nanoparticle (LNP) PRINT delivery platform. The technology is designed to produce "PRINTed" therapeutics targeting both chronic and rare diseases. Initial disease-related non-human primate studies are scheduled for 2026 as the company advances its preclinical pipeline. The company is led by CEO Ron Park, M.D., with a leadership team that includes CSO Francine Gregoire, CBO Priya Parameswaran, and other senior executives across operations, IP, and culture. Addition plans to deploy its latest capital to expand operations and scale R&D programs. To date, the company has secured $100 million in external financing, though no revenue or user metrics were disclosed in the article.